Technical Analysis for ALRN - Aileron Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 5.00 | 1.42% | 0.07 |
Earnings due: May 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 1.42% | |
| Boomer Buy Setup | Bullish Swing Setup | 1.42% | |
| Calm After Storm | Range Contraction | 1.42% | |
| NR7 | Range Contraction | 1.42% | |
| Narrow Range Bar | Range Contraction | 1.42% | |
| Inside Day | Range Contraction | 1.42% | |
| Wide Bands | Range Expansion | 1.42% | |
| Calm After Storm | Range Contraction | 5.26% | |
| Lower Bollinger Band Walk | Weakness | 5.26% | |
| Stochastic Reached Oversold | Weakness | 5.26% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 6 hours ago |
| 50 DMA Resistance | about 6 hours ago |
| Rose Above 10 DMA | about 6 hours ago |
| Up 10% | about 6 hours ago |
| Down 1% | about 7 hours ago |
Get a Trading Assistant
- Earnings date: 05/06/2024
Aileron Therapeutics, Inc. Description
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Tumor Inflammation Molecular Biology Lymphoma Cell Biology Metabolic Disease Oncogenes Peptides Hematological Malignancies Proteins P53 Tumor Suppressor Genes Treatment Of A Range Of Cancer Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.42 |
| 52 Week Low | 1.01 |
| Average Volume | 72,943 |
| 200-Day Moving Average | 3.05 |
| 50-Day Moving Average | 5.37 |
| 20-Day Moving Average | 5.62 |
| 10-Day Moving Average | 5.16 |
| Average True Range | 0.71 |
| RSI (14) | 44.75 |
| ADX | 31.74 |
| +DI | 29.54 |
| -DI | 15.12 |
| Chandelier Exit (Long, 3 ATRs) | 5.28 |
| Chandelier Exit (Short, 3 ATRs) | 6.26 |
| Upper Bollinger Bands | 6.96 |
| Lower Bollinger Band | 4.27 |
| Percent B (%b) | 0.24 |
| BandWidth | 47.83 |
| MACD Line | -0.20 |
| MACD Signal Line | -0.06 |
| MACD Histogram | -0.1419 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.35 | ||||
| Resistance 3 (R3) | 5.30 | 5.12 | 5.28 | ||
| Resistance 2 (R2) | 5.12 | 5.01 | 5.14 | 5.26 | |
| Resistance 1 (R1) | 5.02 | 4.94 | 5.07 | 5.07 | 5.23 |
| Pivot Point | 4.84 | 4.84 | 4.86 | 4.86 | 4.84 |
| Support 1 (S1) | 4.74 | 4.73 | 4.79 | 4.79 | 4.63 |
| Support 2 (S2) | 4.56 | 4.66 | 4.58 | 4.60 | |
| Support 3 (S3) | 4.46 | 4.56 | 4.58 | ||
| Support 4 (S4) | 4.51 |
